Symbiotec Pharmalab shareholders and shareholding pattern
NSE: SYMBIOTECBSE: 544889Pharmaceuticals & Biotechnology
Last close ₹1,164.20down ₹33.30 (2.78%)BSE ₹1,164.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,197.50.
Range of traded prices from listing on 1 Sep 2026 to 23 Oct 2026
₹934.20Low, 1 Sep 2026₹1,309.90High, 16 Oct 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹7,481 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No full year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No balance sheet
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Sep 2026
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,58,23231.5% delivered
Who owns Symbiotec Pharmalab, filing by filing
Per cent of the company's shares. Every filing on record, from Sep 2026; the latest is the filing for Sep 2026.
Sep 2026 filing
- Promoters33.28%
- Foreign institutions3.79%
- Indian institutions33.17%
- Individuals and others29.76%
| Per cent | Sep 2026Filed 15 Oct |
|---|---|
| 33.28% | |
| Indian promoters | 33.28% |
| Public. Every shareholder outside the promoter group, the employee trusts and the shares held against depositary receipts, as the filing totals them. | 66.72% |
| Promoter shares pledgedShare of the promoters' own shares | 38.54% |
| Shares in issue | 6,42,56,112 |
| Shares locked inShares locked in. Shares the filing reports as barred from sale until a set day, such as promoters' shares after a public issue or shares allotted to an investor directly. | 3,83,20,754 |
| Promoters' shares locked in | 1,82,04,297 |
Pledged is the share of the promoters' own shares given to lenders as security. A dash is a line the filing did not state. “Under 0.01%” is a holding of shares too small to show at two decimals.
Symbiotec Pharmalab promoters
Promoters are the founders, families and companies that control the company, as its filings name them. Every member of the promoter group holding shares in the filing for Sep 2026; the largest is Satwani Holdings LLP, 15.28%.Promoter buying and selling
| Holder | ||||
|---|---|---|---|---|
| Satwani Holdings LLPIndian companies, trusts and others | 15.28% | 98,19,885 | 22.69% | 77.31% |
| Anil SatwaniIndividuals and Hindu undivided families | 11.75% | 75,59,104 | 16.04% | 83.96% |
| Kashish SatwaniIndividuals and Hindu undivided families | 4.28% | 27,50,896 | 18.21% | 81.79% |
| Sushil SatwaniIndividuals and Hindu undivided families | 1.92% | 12,33,938 | 25.44% | 100.00% |
| Swati SachdevIndividuals and Hindu undivided families | 0.02% | 10,000 | 0.00% | 100.00% |
| Sunil SatwaniIndividuals and Hindu undivided families | 0.02% | 10,000 | 0.00% | 100.00% |
Pledged is the share of the holder's own shares pledged to a lender. Locked in is the share of the holder's own shares that cannot be sold yet, as after a listing or an allotment.
Symbiotec Pharmalab lock-in dates
At listing on 1 Sep 2026, 68.7% of the shares were locked in; the rest were free to sell from that day.
| Free to sell fromShares locked in. Shares the rules for a public issue bar from being sold until a set day: the promoters' and the anchor investors' shares, and the shares held before the issue. | Shares | Of all shares |
|---|---|---|
| 26 Sep 2026 | 26,62,949 | 4.14% |
| 25 Nov 2026 | 26,62,960 | 4.14% |
| 28 Feb 2027 | 2,59,80,320 | 40.43% |
| 28 Feb 2028 | 1,28,57,000 | 20.01% |
Each day a lock ends and the shares it frees, as a share of all the company's shares after the issue.
Largest public holders of Symbiotec Pharmalab, filing by filing
Per cent, on the same shares as the split above.Mutual funds holding Symbiotec Pharmalab
| Holder | Sep 2026Filed 15 Oct |
|---|---|
| Rosewood InvestmentsForeign companies | 14.07% |
| Business Excellence Trust Iii - India Business Excellence Fund IiiAlternative investment funds | 10.24% |
| Valuequest Founders Conviction LvfAlternative investment funds | 2.92% |
| Think India Opportunities Master Fund LpForeign companies | 2.76% |
| Pi Opportunities Aif V LlpAlternative investment funds | 1.78% |
| Dymon Asia Multi-Strategy Investment (Singapore) Pte. LtdForeign companies | 1.58% |
| Vq Fastercap Fund IiAlternative investment funds | 1.03% |
A filing names every holder above one per cent, in the company's own words: an insurer's holding can carry one of its funds' names. Mutual funds are left out here: each fund's holding is on the Mutual funds tab, from its own portfolio. A dash is a filing that did not name the holder, which includes holding under one per cent.